Universal Diagnostics: Funding, Investors & Team (Sep 2026)
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus is on developing non-invasive blood-based solutions for the early detection of cancer, during a time when treatment options are more abundant and survival rates are higher. UDX strongly believes that detecting cancer at an early stage is the most effective way to combat it. Their diagnostic platform is designed to identify various types of cancer, such as colorectal, prostate, liver, pancreatic, lung, and breast cancer (which accounts for over 50% of all new cancer cases per year), through a single blood test. This is made possible by using a curated collection of proprietary methylation markers. The blood sample can be taken during a routine check-up and then processed at a reference laboratory or hospital using standard equipment. The results are then uploaded to the UDX Cloud for final analysis using an algorithm. UDX's initial marker panel focuses on screening for colorectal cancer, which helps identify individuals who should be referred for colonoscopy. Colorectal cancer is the third most common cancer and the second most deadly cancer worldwide. However, it is often detected at later stages, resulting in significantly lower survival rates (11% in stage IV compared to 85% in stage I). To support the development of their test and carry out necessary research and operations, UDX collaborates with international research institutions, hospitals, universities, and biobanks across the globe.
Universal Diagnostics has raised $126M across 4 funding rounds on record, the most recent an undisclosed round of $34.9M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Universal Diagnostics Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Universal Diagnostics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Universal Diagnostics raised $70.2M in a Series B announced in Nov 2023.
9 months later, a Series B was announced in Aug 2024 with no disclosed amount.
6 months later, an undisclosed round of $21.0M was announced in Feb 2025.
11 months later, an undisclosed round of $34.9M was announced in Jan 2026.
Universal Diagnostics Founders and Leadership Team
Contact details for the Universal Diagnostics team: 1 of 1 has an email address on file.
Start 14-day free trial →Universal Diagnostics Funding Compared to Other Biotechnology Startups
Universal Diagnostics' latest round of $34.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Universal Diagnostics in Biotechnology and Seville
Companies Similar to Universal Diagnostics
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological…
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic…
IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues…
Molecular Gate refer to an innovative class of small-molecule drugs developed by Gate Bioscience. These drugs…
Modern medicine fails because it studies life in static environments. 60Nd revolutionizes the field with…
Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The…
Phyture Biotech originated as a spin-off of the Faculty of Pharmacy at the University of Barcelona, founded…
Polimerbio offers sanitary product design and development based on biocompatible polymers, particularly…
Overture Life is a biotechnology company that specializes in developing automated technologies for assisted…
In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun…
Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of…
Universal Diagnostics Funding FAQs
What does Universal Diagnostics do?
Universal Diagnostics S.A. (UDX) is a company in Spain that specializes in in-vitro diagnostics. Their focus is on developing non-invasive blood-based solutions for the early detection of cancer, during a time when treatment options are more abundant and survival rates are higher. UDX strongly believes that detecting cancer at an early stage is the most effective way to combat it. Their diagnostic platform is designed to identify various types of cancer, such as colorectal, prostate, liver, pancreatic, lung, and breast cancer (which accounts for over 50% of all new cancer cases per year), through a single blood test. This is made possible by using a curated collection of proprietary methylation markers. The blood sample can be taken during a routine check-up and then processed at a reference laboratory or hospital using standard equipment. The results are then uploaded to the UDX Cloud for final analysis using an algorithm. UDX's initial marker panel focuses on screening for colorectal cancer, which helps identify individuals who should be referred for colonoscopy. Colorectal cancer is the third most common cancer and the second most deadly cancer worldwide. However, it is often detected at later stages, resulting in significantly lower survival rates (11% in stage IV compared to 85% in stage I). To support the development of their test and carry out necessary research and operations, UDX collaborates with international research institutions, hospitals, universities, and biobanks across the globe.
How much funding has Universal Diagnostics raised?
Universal Diagnostics has raised $126M across 4 rounds on record. The most recent is an undisclosed round of $34.9M announced in Jan 2026.
When did Universal Diagnostics last raise funding?
Universal Diagnostics' most recent funding round on record is an undisclosed round of $34.9M, announced in Jan 2026.
Who founded Universal Diagnostics?
FundedIQ lists Marko Bitenc (Founder) at Universal Diagnostics.
Where is Universal Diagnostics headquartered?
Universal Diagnostics is based in Seville, Andalucia, Spain.
How many employees does Universal Diagnostics have?
Universal Diagnostics is in the 51-100 employee band.
How does Universal Diagnostics' funding compare to other Biotechnology startups?
Universal Diagnostics' latest round of $34.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Universal Diagnostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Universal Diagnostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.